We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gut-directed therapy in Parkinson's disease.
- Authors
Benvenuti, Laura; Di Salvo, Clelia; Bellini, Gabriele; Seguella, Luisa; Rettura, Francesco; Esposito, Giuseppe; Antonioli, Luca; Ceravolo, Roberto; Bernardini, Nunzia; Pellegrini, Carolina; Fornai, Matteo
- Abstract
Parkinson's disease (PD) is a common and slow-progressing neurodegenerative disorder characterized by motor and non-motor symptoms, including gastrointestinal (GI) dysfunctions. Over the last years, the microbiota-gut-brain (MGB) axis is emerging as a bacterial-neuro-immune ascending pathway that contributes to the progression of PD. Indeed, PD patients are characterized by changes in gut microbiota composition, alterations of intestinal epithelial barrier (IEB) and enteric neurogenic/inflammatory responses that, besides determining intestinal disturbances, contribute to brain pathology. In this context, despite the causal relationship between gut dysbiosis, impaired MGB axis and PD remains to be elucidated, emerging evidence shows that MGBaxis modulation can represent a suitable therapeutical strategy for the treatment of PD. This review provides an overview of the available knowledge about the beneficial effects of gut-directed therapies, including dietary interventions, prebiotics, probiotics, synbiotics and fecal microbiota transplantation (FMT), in both PD patients and animal models. In this context, particular attention has been devoted to the mechanisms by which the modulation of MGB axis could halt or slow down PD pathology and, most importantly, how these approaches can be included in the clinical practice.
- Subjects
PARKINSON'S disease; FECAL microbiota transplantation; DEEP brain stimulation; GUT microbiome; BRAIN diseases; MOVEMENT disorders
- Publication
Frontiers in Pharmacology, 2024, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2024.1407925